הכנסה תפעולית לפני ניכוי פחת: Vanda Pharma (VNDA)

The implementation of automated CNS molecule screening optimizes research, as confirmed by the monthly EBITDA trend, where the figure is recorded at 0.00. Growth is based on the patent protection of Hetlioz and strong pricing power within niche markets. The integration of precision neurotherapy into schizophrenia treatment standards creates an indispensable foundation for the business development of Vanda Pharmaceuticals (VNDA).

This indicator measures the business's daily ability to generate cash flow from core operations, excluding non-cash asset depreciation expenses. For Vanda Pharmaceuticals (VNDA), whose developments are protected by a sovereign demand cycle, this underlying operational result before depreciation confirms the company's resilience as a defensive asset, reflecting the real efficiency of drug commercialization without the influence of macroeconomic fluctuations.